WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • WJPPS: MARCH ISSUE PUBLISHED
  • March Issue has been successfully launched on 1 March 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

Abstract

PHARMACOKINETICS AND ENHANCED ORAL BIOAVAILABILITY IN ALBINO RABBITS OF SIMVASTATIN NANOPARTICLES

Anilkumar J. Shinde*, Harinath N. More

ABSTRACT

Aims: The aim of the study was to compare the single dose oral bioavailability of simvastatin nanoparticles (SV), Simvastatin pure drug and marketed tablet formulation in albino rabbits. Study design: Plasma was analyzed for simvastatin using a sensitive, reproducible, accurate and validated RP-HPLC method. Pharmacokinetic parameters including AUC, Cmax, Tmax, t1/2, MRT and Kel were determined from plasma concentration of the simvastatin nanoparticles, simvastatin pure drug and marketed tablet formulations. Methodology: Albino rabbits were grouped as standard I (6), Standard II (6) and Test (6). Simvastatin pure drug and simvastatin marketed formulation were administered to standard group. Simvastatin loaded nanoaprticles suspension was administered to test group. The pharmacokinetic parameters of SV nanoparticles, SV pure and SV marketed tablets were compared in albino rabbits. Results: Cmax of SV nanoparticles was found to be 63.35±0.195 ng/ml, whereas Cmax value for the drug suspension and marketed tablet formulation was found to be 34.00 ± 0.100 ng/ml and 46.91± 0.194 ng/ml respectively (p < 0.001). AUC (0–8h) value for the simvastatin nanoparticles, drug suspension and marketed tablet formulation were found to be 235.36 ± 0.101 (ng/ml×h), 152.72±0.20 (ng/ml×h) and 189.22± 0.23 (ng/ml×h) respectively (p<0.001). The results revealed that relative bioavailability (Fr %) was increased as compared to oral control group standard I and II. Conclusion: Simvastatin nanoparticles showed a significant improvement in bioavailability as compared with the pure drug and conventional marketed tablet.

Keywords: Bioavailability, Pharmacokinetics, RPHPLC, Simvastatin, Nanoparticles.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More